Your dermatologist treats the skin. Your gastro treats the gut. Your GP treats the joint pain. Nobody's treating the switch underneath all three.
Instant PDF download. Yours to keep — no subscription.
Get the guide — $10.99 →Instant PDF delivery · Secure Stripe checkout · Research-only, not medical advice
The anti-inflammatory tripeptide no one's talking about — one switch, five symptoms.
KPV is a tripeptide fragment of alpha-MSH that works on the shared root of inflammation — NF-κB, the master inflammatory switch.
That's why a single small peptide keeps appearing across gut, skin, joints, mast cells and hair. It isn't five different drugs — it's one mechanism reaching five places.
The guide is built around that idea, because it does real self-selection: if arthritis, eczema, gut issues and flare-ups keep overlapping for you, they may share a cause. Every headline number here is animal or cell data, and it's labelled that way — none of it is human trial data yet.
A complete, plain-English breakdown — with each figure marked by the study type it came from.
NF-κB — the one switch under five symptoms
The corticosteroid comparison, without the steroid downsides
Gut inflammation and bacterial translocation — the replicated data
Mast cells, histamine and MCAS reactivity
Separate antimicrobial action against S. aureus and Candida
A conservative subcutaneous protocol, and the honest timeline
None of KPV's headline numbers are human yet — so every one is labelled animal, cell, or mechanism. That honesty is the point.
30–45% reduction in arthritis severity, comparable to a corticosteroid — without the weight gain, metabolic disruption or bone loss of long-term steroids.
40–70% lower gut inflammatory cytokines and 58% less bacterial translocation — KPV's single most replicated finding.
Directly reduces mast-cell degranulation — one of the few peptide mechanisms addressing histamine/MCAS reactivity at its source.
Separate, genuine antimicrobial action against S. aureus and Candida at low concentrations.
No hormonal side effects — it keeps alpha-MSH's anti-inflammatory punch without the tanning or appetite effects.
A conservative subcutaneous protocol built for 60–80% bioavailability — plus the honest timeline: the biology moves in hours, the feeling moves in weeks.
You could ask an AI about KPV and get a confident answer in seconds. It'll also invent citations, quietly blend animal results into human ones, and round the flattering numbers up. A good part of this industry runs on exactly that.
Every Lumen guide is the opposite: a person reads the primary research, writes it in plain English, and edits it line by line before it ships — and nothing goes in that can't be traced to a real source.
Hand-researched and edited. Written and checked from primary sources by a person — not an unread, auto-generated dump.
Every claim cited and labelled. Each figure shows the evidence behind it — human, animal, mechanism, or trial data.
Written in plain English. The mechanism, the maths and the protocol, made readable — no pharmacology degree required.
No reviews we can't verify. We'd rather leave the space empty than fake a testimonial.
Instant delivery, yours to keep. A downloadable PDF the moment you check out — no account, no subscription.
No controlled human trial of KPV exists yet, and it's not currently on the FDA 503A list — with a PCAC decision that could shift access. Every percentage on this page is labelled by the study type it came from, and this page is for research and educational use only.
Instant PDF delivery. Every figure labelled by evidence type. The honest, sourced breakdown of a tripeptide most people miss.
Get the guide — $10.99 →One-time · instant download · research & educational use only
Verified reviews from people who actually bought this guide.
New research drops and dosing updates, straight to your inbox. No spam, unsubscribe anytime.